[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Min-Tze LIONG\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":195},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,76,100,122,146,173],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100632297","phase-2-stress-buffering-and-sleep-disturbance-resilient-effects-of-a-dual-bifidobacterium-longum-combination-under-short-term-travel-100632297",false,"NCT07511855","Stress-buffering and Sleep Disturbance-resilient Effects of a Dual Bifidobacterium Longum Combination Under Short-term Travel","Stress-buffering and Sleep Disturbance-resilient Effects of a Dual Bifidobacterium Longum Combination Under Short-term Travel: A Randomized, Double-blind, Placebo-controlled Study","Inclusion Criteria:\n\n* Willing to participate in this study and able to provide written informed consent before any study procedures are initiated.\n* Able and willing to comply with all study procedures as required by the protocol, including continuous wearable device use, saliva and stool sample collection, and completion of questionnaire assessments.\n* Willing to accept randomization and group allocation as determined by the study protocol.\n\nExclusion Criteria:\n\n* Known use of antibiotics or systemic corticosteroids within 4 weeks prior to enrollment.\n* Use of probiotic supplements within 4 weeks prior to enrollment.\n* Planned use of any probiotic supplements during the study period.\n* Known history or current presence of major endocrine disorders, active inflammatory bowel disease or other severe gastrointestinal diseases, or severe sleep disorders requiring treatment adjustment.\n* Pregnant or intend to get pregnant, or lactating women.\n* Known allergy to any probiotic products.\n* Participation in any other clinical interventional study involving drugs, dietary supplements, probiotics, or prebiotics within the past three months.\n* Or those who, according to the researcher's judgment, may have inadequate adherence or are unable to complete the study protocol.",true,"ALL","25 Years","50 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This study aims to evaluate the effects of a dual Bifidobacterium longum probiotic formulation (dipro-O and dipro-X) on sleep quality, stress responses, and gut microbiota stability in healthy adults during short-term travel. Using a randomized, double-blind, placebo-controlled design, the study investigates whether probiotic supplementation can enhance sleep resilience, buffer stress, and modulate microbiome and physiological responses under travel-related environmental changes.",[28],"Healthy",[30,31,32,33,34],"probiotic","Bifidobacterium","short term travel","sleep","gut microbiota","NOT_YET_RECRUITING","2026-06-29",{"date":38,"type":39},"2026-07-02","ACTUAL",{"date":41,"type":22},"2026-07-01",{"date":43,"type":22},"2027-05-31",{"name":45,"class":46},"Min-Tze LIONG","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100615850","phase-2-evaluation-of-the-clinical-efficacy-of-antrrix-probiotics-in-improving-recurrent-respiratory-infections-in-infants-and-young-children-100615850","NCT07297966","Evaluation of the Clinical Efficacy of Antrrix Probiotics in Improving Recurrent Respiratory Infections in Infants and Young Children","Inclusion Criteria:\n\n* Age \\\u003C 6 years, gender not limited;\n* Meets the clinical diagnostic criteria for recurrent respiratory tract infections (Clinical Diagnosis and Treatment Pathway for Recurrent Respiratory Tract Infections in Children (2022 Edition) 10 );\n* Parents or other legal guardians of the child fully understand the trial and voluntarily sign informed consent forms before the start of any research procedure;\n* Willing to discontinue the use of other probiotics during the trial;\n* Agree to the collection of fecal biological samples during this trial.\n\nExclusion Criteria:\n\n* Those deemed by the investigator to have poor compliance or be unsuitable for participation;\n* Allergic to the investigational product and its components;\n* Allergic to respiratory tract infection drugs and their components;\n* Respiratory infections caused by underlying diseases such as primary immunodeficiency diseases, acquired immunodeficiency syndrome (ADRS), congenital airway malformations, congenital heart disease, gastroesophageal reflux disease (GERD), and pulmonary dysplasia;\n* Patients with severe malnutrition, rickets, and severe primary diseases of the heart, brain, liver, kidney, and hematopoietic systems;\n* Use probiotic preparations, antibiotics, immunostimulants, or immunosuppressants 4 weeks before participating in the experiment.","1 Day","6 Years",{"count":57,"type":22},120,[25],"This study is an 8-weeks, randomized controlled trial involving children under 6 years of age who meet clinical diagnostic criteria for RRTI. Participants are randomized to receive either probiotic or placebo. The primary clinical outcomes assessed are duration and frequency of respiratory symptoms and quality of life. To investigate potential mechanisms, stool samples were collected pre- and post-intervention for metagenomics gene sequencing to analyze changes in gut microbiota composition and identify specific bacterial taxa associated with clinical improvements.",[61],"Recurrent Respiratory Tract Infections",[63,30,64,65],"RRTI","RCT","children","RECRUITING","2026-04-14",{"date":69,"type":39},"2026-04-17",{"date":71,"type":39},"2025-05-14",{"date":73,"type":22},"2026-06-30",{"name":45,"class":46},2,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":16,"sex":17,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":99,"locationsCount":75},"100630662","phase-2-to-investigate-the-effects-of-bifidobacterium-animalis-subsp-lactis-xltg11-on-growth-and-development-incidence-of-allergy-and-immune-function-in-infants-100630662","NCT07490587","To Investigate the Effects of Bifidobacterium Animalis Subsp. Lactis XLTG11 on Growth and Development, Incidence of Allergy and Immune Function in Infants","Inclusion Criteria:\n\n* Term infants are 37≤ gestational age \\\u003C 42 weeks, and the birth weight is between 2500g and 4000g (only applicable to 0\\~12 months old)\n* Breastfed or mixed-fed healthy infants and young children, aged 0\\~3 (inclusive) years old, gender is not limited\n* The allergy risk score calculated by the Infant Allergy Risk Assessment Table is ≥6(Refer to the National Center for Women and Children's Health, Chinese Center for Disease Control and Prevention: Investigation and Research on Allergy Symptoms and Risk Factors in Infants and Young Children)\n* Family primary guardians agree to collect fecal samples of infants and young children during this study\n* Have not used antibiotics in the past month\n* Have not used probiotics in the past three months\n* Family primary guardians committed not to add additional Bifidobacterium dietary supplements to infants and young children during the intervention period\n* The guardians of the enrolled subjects agree to participate in this interventional study and sign a written informed consent form, and are able to understand and fill in forms such as infant diaries as required\n* Signed informed consent and willing to follow up at the time specified in the trial\n\nExclusion Criteria:\n\n* The mother of the infant has a history of diabetes, hepatitis B, HIV and other infectious diseases\n* Clinicians diagnosed with allergic diseases (including but not limited to eczema, asthma, allergic proctocolitis, allergic rhinitis, hay fever, etc.) at the time of enrollment of infants and young children\n* Infants and young children who are known to be allergic to the ingredients of probiotic products\n* In the opinion of the investigator, the subject has other reasons that make it unsuitable to participate in this clinical study","0 Months","36 Months",{"count":85,"type":22},366,[25],"This study is a 180-day randomized, double-blind, placebo-controlled trial involving healthy infants and young children under 3 years of age with elevated allergy risk. Participants are randomized to receive either Bifidobacterium animalis subsp. lactis XLTG11 probiotic or placebo daily. The primary clinical outcomes assessed are incidence and day-level burden of allergic, respiratory, and gastrointestinal symptoms. To investigate potential mechanisms, fecal samples were collected pre- and post-intervention for shotgun metagenomic sequencing to analyze changes in gut microbiota composition, functional pathways (KEGG, COG, GO), and mucosal immune markers (β-defensin 2, LL-37, calprotectin, sIgA) associated with clinical improvements.",[89],"Healthy Children",[65,30,91,92],"allergy","bifidobacterium","2026-03-26",{"date":95,"type":39},"2026-04-01",{"date":97,"type":39},"2024-01-01",{"date":73,"type":22},{"name":45,"class":46},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":16,"sex":17,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":121,"locationsCount":75},"100622071","integrated-study-on-gut-microbiota-immune-indicators-and-trace-elements-in-children-with-respiratory-tract-infections-100622071","NCT07378852","Integrated Study on Gut Microbiota, Immune Indicators, and Trace Elements in Children With Respiratory Tract Infections","Inclusion Criteria\n\n1. Aged 3-14 years;\n2. Good compliance and complete clinical data;\n3. Guardians are informed and sign written consent;\n4. MPP group: meets diagnostic criteria of Guidelines for Diagnosis and Treatment of Mycoplasma Pneumoniae Pneumonia in Children (2023 Edition);\n5. NMP group: acute respiratory tract infection with negative MP-DNA\u002FRNA;\n6. RRTIs group: meets diagnostic criteria of Clinical Diagnosis and Treatment Pathway for Recurrent Respiratory Tract Infections in Children (2022 Edition);\n7. Healthy controls: no respiratory infection history within the past month.\n\nExclusion Criteria\n\n1. Other infectious diseases (e.g., measles, pertussis, tuberculosis);\n2. Congenital heart disease, immunodeficiency, or major organ dysfunction;\n3. Use of antibiotics, probiotics, immunomodulators, hormones, or microecological preparations within the past 15-30 days;\n4. Unqualified biological samples or incomplete laboratory data.","3 Years","14 Years",{"count":57,"type":22},"OBSERVATIONAL","This observational study aims to investigate the characteristics of gut microbiota and their associations with immune and nutritional indicators in children with different respiratory health statuses. A total of 120 children will be enrolled and categorized into four groups: children with Mycoplasma pneumoniae pneumonia (MPP), children with acute respiratory tract infections without Mycoplasma pneumoniae (NMP), children with recurrent respiratory tract infections (RRTIs), and healthy controls. By comparing gut microbiota composition and diversity, as well as immune- and nutrition-related indicators across groups, this study seeks to clarify the potential role of intestinal dysbiosis and host immune-nutritional interactions in the pathogenesis and clinical manifestations of pediatric respiratory tract infections.",[112],"Respiratory",[65,114,34],"respiratory","2026-02-01",{"date":117,"type":39},"2026-02-04",{"date":119,"type":22},"2026-01-30",{"date":73,"type":22},{"name":45,"class":46},{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":16,"sex":17,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":143,"leadSponsor":145,"locationsCount":75},"100622487","phase-2-the-effect-of-probiotics-on-gut-microbiota-changes-in-healthy-chinese-adults-during-short-term-european-travel-a-randomised-double-blind-placebo-controlled-clinical-trial-100622487","NCT07384260","The Effect of Probiotics on Gut Microbiota Changes in Healthy Chinese Adults During Short-Term European Travel: A Randomised, Double-Blind, Placebo-Controlled Clinical Trial","The Effect of","Inclusion criteria:\n\n1. Aged 18-65 years, regardless of gender;\n2. Planning to undertake a short-term round-trip journey to Europe (within 7 days);\n3. Able to understand and willing to comply with the study protocol, and to cooperate with study procedures;\n4. Voluntarily sign the informed consent form before any study-related procedures are initiated.\n\nExclusion criteria:\n\n1. Diseases that may affect the evaluation of trial results, such as immune dysfunction, severe renal\u002Fhepatic dysfunction, severe cardiovascular disease, malignant tumors, acute or chronic infections, etc.;\n2. Use of probiotic preparations, antibiotics, hormones, immunosuppressants, biological agents, or JAK inhibitors within 4 weeks;\n3. Subjects with diagnosed or uncontrolled parasitic infections;\n4. Patients receiving long-term medication for chronic diseases;\n5. Patients with severe organic lesions in the thyroid, heart, brain, lungs, kidneys, or musculoskeletal system;\n6. Patients with a history of or currently diagnosed mental illness;\n7. Patients on long-term corticosteroid therapy;\n8. Use of growth hormone, γ-aminobutyric acid (GABA), lysine, inositol, or vitamin B12;\n9. Presence of uncontrolled, clinically significant laboratory abnormalities that may affect data interpretation or subject participation;\n10. Participation in other clinical intervention studies involving drugs, dietary supplements, probiotics, or prebiotics within the past 4 weeks;\n11. Presence of severe infections or major trauma deemed by the investigator to potentially affect outcomes, or having undergone moderate to major surgery within the past month;\n12. Known allergy to any component of the probiotic product;\n13. Subjects deemed unsuitable for participation by the investigator for any other reason.","18 Years","65 Years",{"count":132,"type":22},40,[25],"This study aims to evaluate the efficacy of a probiotic complex (containing Bifidobacterium animalis subsp. lactis B94 and Lacticaseibacillus helveticus R0052) in maintaining gut microbiota homeostasis and supporting physiological and psychological stability among healthy Chinese adults during short-term travel to Europe.",[136],"Healthy Adult",[30,138],"international travel","2026-01-28",{"date":141,"type":39},"2026-02-03",{"date":115,"type":22},{"date":144,"type":22},"2027-01-31",{"name":45,"class":46},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":153,"minAge":129,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":23,"phases":157,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":75},"100552527","phase-2-postbiotic-as-adjunct-treatment-for-vaginal-candidiasis-100552527","NCT06474247","Postbiotic as Adjunct Treatment for Vaginal Candidiasis","Use of Postbiotic as Adjunct Treatment for Vaginal Candidiasis in Women","Inclusion criteria\n\n* Women who are sexually active\n* Confirmed with candidiasis as confirmed via clinical observations which include creamy whitish vaginal discharge and vulva-vaginal itchiness\n* Willing to commit throughout the experiment\n\nExclusion criteria\n\n* Long term medication (6 months or more) for any illnesses\n* Pregnant\n* Menopaused\n* Uterus and\u002For cervix removed\n* Cervical intraepithelial neoplasia\n* Vaginal suppository treatments within 4-weeks prior to entering the study\n* Oral medication for vaginal illnesses or any vaginal therapy such as hormones and estrogen within 4-weeks prior to entering the study\n* Have used vaginal estrogen cream, ring or tablet within 4-weeks prior to entering the study\n* Have used vaginal moisturizers, lubricants or homeopathic preparations within 4-weeks prior to entering the study\n* Have used spermicide agent within 4-weeks prior to entering the study\n* Have pelvic or any gynecologic surgery 6-months prior to entering the study","FEMALE","81 Years",{"count":156,"type":22},118,[25,158],"PHASE3","This project aims to study the efficacy of intravaginal administration of postbiotic at 1g\u002Fday as an adjunct treatment against vaginal candidiasis in women for 4-weeks compared to placebo.",[161],"Vaginal Candidiasis",[30,163,164],"postbiotic","vaginal candidiasis","2024-07-02",{"date":167,"type":39},"2024-07-05",{"date":169,"type":39},"2024-06-02",{"date":171,"type":22},"2025-06-02",{"name":45,"class":46},{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":16,"sex":17,"minAge":179,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":23,"phases":182,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":47},"100552526","phase-2-modulation-of-gut-microbiota-by-probiotic-in-children-100552526","NCT06474234","Modulation of Gut Microbiota by Probiotic in Children","Inclusion criteria\n\n* Preschool children (\\\u003C7 years old)\n* Born full-term (≥37 weeks delivered)\n* In generally good health as determined by the investigator\n\nExclusion criteria\n\n* Had taken probiotics or prebiotics within past 4-weeks\n* Had taken milk powder or supplements containing probiotics within past 4-weeks\n* History of using antibiotic within past 4-weeks\n* Suffering from serious acute or chronic diseases (cardiovascular disease, gastrointestinal disease, endocrine disease, immune system disease, metabolic disease, etc.)\n* Using other drugs that may interfere with the experimental results\n* Participated in other experimental trials less than 8-weeks prior to this study","1 Month","7 Years",{"count":57,"type":22},[25],"This project aims to study the benefits of probiotics namely Bifidobacterium infantis YLGB-1496 in modulating gut microbiota of healthy children, among pre-school children in Malaysia \\\u003C7 years old.",[185],"Generally Healthy",[31,30,65],"2024-06-19",{"date":189,"type":39},"2024-06-25",{"date":191,"type":39},"2024-05-29",{"date":193,"type":22},"2025-06-30",{"name":45,"class":46},""]